Tuesday, September 1
Good earnings mean nothing when bond yields spike
Three companies beat their numbers and raised their outlooks today, then watched their stocks fall anyway as rising government borrowing costs spooked the whole software and tech sector.
Top Stories
Rising bond yields are punishing good news as hard as bad news
Oracle, Palo Alto Networks, and Dell all had legitimate reasons to celebrate today — Oracle is sitting on a $638 billion order backlog, Palo Alto beat estimates and guided well above what analysts expected, and Dell raised its annual revenue outlook by $25 billion on the back of surging demand for AI servers — yet all three stocks fell more than 5%, with Dell dropping nearly 7%, as rising long-term government borrowing costs made investors flee technology stocks broadly.
When bond yields climb to multi-decade highs, the math on future profits gets uglier, and high-growth tech companies are the first to feel that repricing — it does not matter how strong the underlying business looks if the discount rate investors apply to future earnings is moving sharply against them.
GoPro is abandoning its camera business entirely to become an AI and defense company
GoPro announced a merger with Starman Optical, a private photonics firm, pivoting the company away from consumer cameras and into AI data centers and defense technology, a move that sent the stock up more than 40% and was amplified by a reported stake from YouTube star Markiplier and a short squeeze that caught bearish traders badly offside.
The rally is a reminder that a credible pivot story plus retail momentum plus a crowded short position is one of the most explosive combinations in markets — the fundamentals of the new business barely matter on day one.
Novartis delivered a clinical win and a safety crisis simultaneously
Novartis reported that its oral multiple sclerosis drug remibrutinib beat a rival treatment in a late-stage trial, driving the stock up more than 6%, but the company also disclosed it had paused eight clinical trials of a separate experimental therapy after three patients died in late August.
The split verdict captures why drug company investing is so difficult — a single pipeline can deliver a genuine medical advance and a serious safety crisis simultaneously, and the market's net reaction tells you very little about which story will matter more in a year.
Also Today
- Medtronic beat estimates and raised its full-year outlook
- Ford recalling nearly 150,000 vehicles over power and visibility failures
- WPP cutting up to 1,000 more jobs under new leadership
Takeaway
Today's session was less about any individual company's results and more about what rising bond yields do to investor appetite for future growth — strong earnings from multiple companies were simply not enough to overcome that headwind.
The most concrete thing to watch next is whether bond yields stabilize or keep climbing, because until that pressure eases, even genuinely good corporate news is likely to keep getting sold.
